AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29142926 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 1436
Study 29142926 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan (restricted enrollment to classes 1C to E)
Number of subjects: 1436
Study 24668862 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hypercaloric diet for 6 weeks (HFHS)
Number of subjects: 36
Study 24668862 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hypercaloric diet for 6 weeks (HS)
Number of subjects: 36
Study 24668862 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hypercaloric diet with high meal frequency (HFHS)
Number of subjects: 36
Study 24668862 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% hypercaloric diet with high meal frequency (HS)
Number of subjects: 36
Study 24668862 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric control diet
Number of subjects: 36
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management (NM) with 4 visits over 1 year
Number of subjects: 465
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management (NM) plus telemedicine (T)
Number of subjects: 465
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse management (NM)
Number of subjects: 465
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (T)
Number of subjects: 465
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk subjects (Framingham score ≥ 20%)
Number of subjects: 465
Study 21315219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-risk subjects (Framingham score ≥ 10, < 20)
Number of subjects: 465
Study 19747435 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaohe Ganpi Hexin Decoction (TGHD)
Number of subjects: 40
Study 19747435 — intervention group
Group type: COMPARATOR
Intervention: Oral pinaverium (Control)
Number of subjects: 40
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker, metoprolol
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: angiotensin-converting enzyme inhibitor, ramipril
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydropyridine calcium channel blocker, amlodipine
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: usual-blood pressure treatment goal
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: low-blood pressure treatment goal
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 1094
Study 17059993 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 1094
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-oesophageal reflux disease symptoms
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cardiac chest pain
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspepsia
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Globus
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid feeling in the stomach
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of non-steroidal anti-inflammatory drugs
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression scores
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Days off work
Number of subjects: 2209
Study 12969086 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care-seeking behaviour
Number of subjects: 2209
Study 11482713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress (start dose 5 microg/kg/min to maximum dose 15 microg/kg/min)
Number of subjects: 12
Study 11482713 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stress (control group)
Number of subjects: 12
Study 9379401 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual nucleofragmentation (NF) with the Keener nucleus divider
Number of subjects: 51
Study 9379401 — intervention group
Group type: COMPARATOR
Intervention: Planned extracapsular cataract extraction (ECCE)
Number of subjects: 51
Study 9379401 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual nucleofragmentation (NF)
Number of subjects: 51
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 2.5 mg
Number of subjects: 0
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 5 mg
Number of subjects: 0
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg
Number of subjects: 0
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 0.5 mg
Number of subjects: 0
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of Quinapril
Number of subjects: 0
Study 1312002 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses above 2.5 mg of Quinapril
Number of subjects: 0
Study 2858217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (65 mg every 6 h) with Alprazolam (1.0 mg orally)
Number of subjects: 0
Study 2858217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (65 mg every 6 h) with Diazepam (10 mg i.v.)
Number of subjects: 0
Study 2858217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (65 mg every 6 h) with Lorazepam (2 mg i.v.)
Number of subjects: 0
Study 31239321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 0
Study 31239321 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (IC) of single-agent chemotherapy
Number of subjects: 0
Study 28422812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer Lactate (RL)
Number of subjects: 68
Study 28422812 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 68
Study 25236326 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Parent Management Training (PMT) program, 10-week self-directed with limited therapist support
Number of subjects: 58
Study 25236326 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Parent Management Training (PMT) program
Number of subjects: 58
Study 25236326 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental engagement in homework assignments
Number of subjects: 58
Study 23684618 — intervention group
Group type: EXPERIMENTAL
Intervention: Single point acupuncture (Shiqizhui, EX‐B8) before menstruation (Group A)
Number of subjects: 600
Study 23684618 — intervention group
Group type: EXPERIMENTAL
Intervention: Single point acupuncture (Shiqizhui, EX‐B8) immediately treating as soon as pain occurrence (Group B)
Number of subjects: 600
Study 23684618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-points acupuncture before menstruation (Group C)
Number of subjects: 600
Study 23684618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-points acupuncture immediately treating as soon as pain occurrence (Group D)
Number of subjects: 600
Study 23684618 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, Group E)
Number of subjects: 600
Study 21298640 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at 60 beats per minute through a thin transnasal catheter
Number of subjects: 60
Study 21298640 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (control group)
Number of subjects: 60
Study 21298640 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet ventilation with a fixed rate
Number of subjects: 60
Study 19685375 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs) - 2 capsules of Omacor twice daily
Number of subjects: 51
Study 19685375 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 2 capsules of placebo
Number of subjects: 51
Study 19685375 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 51
Study 19685375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17140278 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 15234425 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the Mediterranean diet (highest tertile of diet score)
Number of subjects: 3042
Study 11177210 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonol (HF) diet including one 150 g onion cake (89.7 mg quercetin) and one 300 ml cup of black tea (1.4 mg quercetin) daily for 14 days
Number of subjects: 36
Study 11177210 — intervention group
Group type: COMPARATOR
Intervention: Low-flavonol (LF) diet with avoidance of flavonols, flavones, and flavanols for 14 days
Number of subjects: 36
Study 9091008 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia (2 ml of 2% mepivacaine)
Number of subjects: 80
Study 9091008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 80
Study 8517130 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation using charge‐balanced pulse trains at various repetition rates (frequencies) and inter‐electrode distances.
Number of subjects: 2
Study 8517130 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation at various electrode placements (basal, medial, apical).
Number of subjects: 2
Study 8517130 — intervention group
Group type: COMPARATOR
Intervention: Speech processor in usual condition.
Number of subjects: 2
Study 3532315 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment with inhaled salbutamol (400 micrograms qds)
Number of subjects: 52
Study 3532315 — intervention group
Group type: COMPARATOR
Intervention: Irregular treatment with inhaled salbutamol (400 micrograms prn)
Number of subjects: 52
Study 30287702 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Acid Etching (Transbond XT)
Number of subjects: 60
Study 30287702 — intervention group
Group type: EXPERIMENTAL
Intervention: Seventh‐generation adhesive materials (Xeno V)
Number of subjects: 60
Study 30287702 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite (Filtek Z350 XT)
Number of subjects: 60
Study 27092860 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM-100
Number of subjects: 72
Study 27092860 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM-500
Number of subjects: 72
Study 27092860 — intervention group
Group type: COMPARATOR
Intervention: AP-100
Number of subjects: 72
Study 27092860 — intervention group
Group type: COMPARATOR
Intervention: AP-500
Number of subjects: 72
Study 24832687 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured conversation about patient goals and preferences for medical treatment
Number of subjects: 8
Study 24832687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured conversation)
Number of subjects: 8
Study 22324939 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium montmorillonite (NovaSil, NS) at a dosage of 3 g day⁻¹ for 3 months
Number of subjects: 186
Study 22324939 — intervention group
Group type: COMPARATOR
Intervention: Calcium montmorillonite (NovaSil, NS) at a dosage of 1.5 g day⁻¹ for 3 months
Number of subjects: 186
Study 22324939 — intervention group
Group type: COMPARATOR
Intervention: FB₁ alone
Number of subjects: 186
Study 22324939 — intervention group
Group type: EXPERIMENTAL
Intervention: FB₁ + 2% NS
Number of subjects: 186
Study 22324939 — intervention group
Group type: COMPARATOR
Intervention: Absolute control group (no FB₁ or NS)
Number of subjects: 186
Study 20669673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongxinluo Capsule (TXLC)
Number of subjects: 100
Study 20669673 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 100
Study 18446123 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit cardiopulmonary bypass (N=30)
Number of subjects: 60
Study 18446123 — intervention group
Group type: COMPARATOR
Intervention: Open circuit cardiopulmonary bypass (N=30)
Number of subjects: 60
Study 16701189 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (Group I)
Number of subjects: 60
Study 16701189 — intervention group
Group type: COMPARATOR
Intervention: 150 mg intravenous magnesium (Group II)
Number of subjects: 60
Study 16701189 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg magnesium added to local anesthetic (Group III)
Number of subjects: 60
Study 16701189 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg magnesium added to local anesthetic (Group IV)
Number of subjects: 60
Study 12888380 — intervention group
Group type: EXPERIMENTAL
Intervention: CME/CEU credit program with on-site demonstration of a CBE technique and a free lunch
Number of subjects: 27
Study 12888380 — intervention group
Group type: COMPARATOR
Intervention: Control group (providers did not receive the education program until after their post-test)
Number of subjects: 27
Study 10602752 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 12
Study 10602752 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 12
Study 9195788 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway intervention initiated in the Emergency Department
Number of subjects: 0
Study 9195788 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway intervention
Number of subjects: 0
Study 1556277 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction on childhood depression (received by 16 teachers)
Number of subjects: 418
Study 1556277 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher ratings using the CDI items (teacher‐CDI)
Number of subjects: 418
Study 1556277 — intervention group
Group type: COMPARATOR
Intervention: Global rating (received by remaining students)
Number of subjects: 418
Study 1556277 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher‐CDI
Number of subjects: 418
Study 4051211 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% nitrous oxide
Number of subjects: 7
Study 4051211 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone (1.4 mg)
Number of subjects: 7
Study 31401165 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5-10 mg/day)
Number of subjects: 2569
Study 31401165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study 29788982 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL) as the first treatment option
Number of subjects: 0
Study 29788982 — intervention group
Group type: COMPARATOR
Intervention: Ureteroscopic treatment
Number of subjects: 0
Study 29788982 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 0
Study 27437316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 80
Study 27437316 — intervention group
Group type: COMPARATOR
Intervention: Total Hip Replacement (THR)
Number of subjects: 80
Study 25608428 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Sp-12
Number of subjects: 0
Study 23194481 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban (0.08 mg/kg intravenous bolus at randomization then 0.100 or 0.140 mg/kg per hour intravenous infusion)
Number of subjects: 13220
Study 23194481 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 13220
Study 23194481 — intervention group
Group type: COMPARATOR
Intervention: UFH plus eptifibatide (started pre-percutaneous coronary intervention and continued per label)
Number of subjects: 13220
Study 23194481 — intervention group
Group type: COMPARATOR
Intervention: UFH plus eptifibatide
Number of subjects: 13220
Study 19763664 — intervention group
Group type: EXPERIMENTAL
Intervention: Amfetamine products
Number of subjects: 23
Study 19763664 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate products
Number of subjects: 23
Study 19763664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 18609695 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (irradiation dose of 20 Gy/10 f/12 d, 40 Gy/20 f/24 d, and 60 Gy/30 f/36 d)
Number of subjects: 46
Study 18609695 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (40 Gy/20 f/24 d and 60 Gy/30 f/36 d)
Number of subjects: 46
Study 18609695 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 46
Study 16117982 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescript-Assist (500 mg capsule BID)
Number of subjects: 25
Study 12049852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/d) during 6 weeks after delivery
Number of subjects: 47
Study 12049852 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 47
Study 10630654 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Based Nursing Intervention (HBNI)
Number of subjects: 96
Study 10630654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 7782526 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement dentures prepared for 48 test subjects
Number of subjects: 95
Study 7782526 — intervention group
Group type: COMPARATOR
Intervention: Improvement of current dentures for 47 test subjects
Number of subjects: 95
Study 7782526 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP1 (infirmity) as a predictor
Number of subjects: 95
Study 1934250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 40 mg/m2
Number of subjects: 55
Study 1934250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 60 mg/m2
Number of subjects: 55
Study 1934250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 90 mg/m2
Number of subjects: 55
Study 1934250 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 135 mg/m2
Number of subjects: 55
Study 6751833 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 ml spacer
Number of subjects: 15
Study 6751833 — intervention group
Group type: COMPARATOR
Intervention: ordinary actuator
Number of subjects: 15
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 400 ms
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 200 ms
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 100 ms
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus duration of 50 ms
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation level of 40 dB SL
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation level of 20 dB SL
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation level of 30 dB SL
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation level of 60 dB SL
Number of subjects: 0
Study 31638883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation level of 10 dB SL
Number of subjects: 0
Study 28872916 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (E-E group)
Number of subjects: 123
Study 28872916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-E group)
Number of subjects: 123
Study 27513247 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management educational program
Number of subjects: 306
Study 24337079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 0.5 mg
Number of subjects: 56
Study 24337079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 3 mg
Number of subjects: 56
Study 24337079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 (0.025-3 mg)
Number of subjects: 56
Study 24337079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836
Number of subjects: 56
Study 24337079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22672253 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 0
Study 22672253 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to the GP requesting treatment according to NICE's 'stepped care' recommendations
Number of subjects: 0
Study 22672253 — intervention group
Group type: COMPARATOR
Intervention: Waiting list arm
Number of subjects: 0
Study 19223156 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 19223156 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 19223156 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitter patients
Number of subjects: 0
Study 19223156 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-remitter patients
Number of subjects: 0
Study 17263633 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine + Lamivudine (ZDV + 3TC)
Number of subjects: 77
Study 17263633 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine + Didanosine (d4T + ddI)
Number of subjects: 77
Study 17263633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (ZDV + 3TC and d4T + ddI)
Number of subjects: 77
Study 17263633 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T + ddI
Number of subjects: 77
Study 17263633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mtDNA level at month 12
Number of subjects: 77
Study 15099657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 330
Study 15099657 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 330
Study 11772695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 223
Study 11772695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 9436069 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple A (Adolescent Asthma Action) program
Number of subjects: 0
Study 8593013 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally every 12 h for five doses
Number of subjects: 6
Study 8593013 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally every 24 h for three doses
Number of subjects: 6
Study 2503289 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily bicycle exercise at 75 W for 1 hour during IVF
Number of subjects: 11
Study 2503289 — intervention group
Group type: COMPARATOR
Intervention: IVF without daily exercise
Number of subjects: 11